A E Czeizel1, M Rockenbauer, H T Sørensen, J Olsen. 1. Department of Human Genetics and Teratology, Foundation for the Community Control of Hereditary Diseases, National Centre for Epidemiology, Torokvesz Lejto 32, 1026, Budapest, Hungary. czeizel@interware.hu
Abstract
OBJECTIVE: To study human teratogenic potential of oral nitrofurantoin treatment during pregnancy. MATERIALS AND METHODS: Pair analysis of cases with congenital abnormalities and matched population controls in the population-based dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1996. RESULTS: Of 38,151 pregnant women who had newborn infants without any congenital abnormalities (population control group), 774 (3.4%); of 22,865 case pregnant women who had newborns or fetuses with congenital abnormalities, 1079 (2.8%) and of 812 pregnant women who had newborns or fetuses with Down's syndrome (patient controls), 23 (2.8%) pregnant women were treated with nitrofurantoin. The above differences between population controls and cases may be connected with recall bias, because the case-control pair analysis did not indicate a teratogenic potential of nitrofurantoin use during the second and the third months of gestation, i.e. in the critical period for major congenital abnormalities. CONCLUSION: Treatment with nitrofurantoin during pregnancy does not present detectable teratogenic risk to the fetus.
OBJECTIVE: To study human teratogenic potential of oral nitrofurantoin treatment during pregnancy. MATERIALS AND METHODS: Pair analysis of cases with congenital abnormalities and matched population controls in the population-based dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1996. RESULTS: Of 38,151 pregnant women who had newborn infants without any congenital abnormalities (population control group), 774 (3.4%); of 22,865 case pregnant women who had newborns or fetuses with congenital abnormalities, 1079 (2.8%) and of 812 pregnant women who had newborns or fetuses with Down's syndrome (patient controls), 23 (2.8%) pregnant women were treated with nitrofurantoin. The above differences between population controls and cases may be connected with recall bias, because the case-control pair analysis did not indicate a teratogenic potential of nitrofurantoin use during the second and the third months of gestation, i.e. in the critical period for major congenital abnormalities. CONCLUSION: Treatment with nitrofurantoin during pregnancy does not present detectable teratogenic risk to the fetus.
Authors: Elizabeth C Ailes; Suzanne M Gilboa; Simerpal K Gill; Cheryl S Broussard; Krista S Crider; Robert J Berry; Tonia C Carter; Charlotte A Hobbs; Julia D Interrante; Jennita Reefhuis Journal: Birth Defects Res A Clin Mol Teratol Date: 2016-11
Authors: Alana Cavadino; Lovisa Sandberg; Inger Öhman; Tomas Bergvall; Kristina Star; Helen Dolk; Maria Loane; Marie-Claude Addor; Ingeborg Barisic; Clara Cavero-Carbonell; Ester Garne; Miriam Gatt; Babak Khoshnood; Kari Klungsøyr; Anna Latos-Bielenska; Nathalie Lelong; Reneé Lutke; Anna Materna-Kiryluk; Vera Nelen; Amanda Nevill; Mary O'Mahony; Olatz Mokoroa; Anna Pierini; Hanitra Randrianaivo; Anke Rissmann; David Tucker; Awi Wiesel; Lyubov Yevtushok; Joan K Morris Journal: Drug Saf Date: 2021-05-09 Impact factor: 5.606